Orthocell Limited
OCC
Rank in Stocks
#19155
Headquartered in Murdoch, Australia, Orthocell Limited, established in 2006,... Headquartered in Murdoch, Australia, Orthocell Limited, established in 2006, operates as a regenerative medicine company focused on creating and bringing to market advanced cell therapies and biological medical devices. These innovations are designed to facilitate the healing of a range of bone and soft tissue injuries. The company's product lineup includes CelGro, a naturally derived collagen medical device engineered to augment surgical repair across various indications, including bone, peripheral nerves, tendons, and cartilage. Another key offering is Ortho-ATI, a specialized cell therapy developed for the treatment of chronic tendon injuries. Furthermore, Orthocell provides Ortho-ACI, an autologous chondrocyte implantation technique aimed at repairing articular cartilage defects in the knee and ankle. Its portfolio also features Striate+, a biodegradable collagen membrane employed for guided bone and tissue regeneration in dental applications, and Remplir, a collagen scaffold utilized for the restoration of peripheral nerves.
Share Price
$0.41531402
Last synced: 2026-11-10
Market Cap
$113.13M
Change (1 day)
0.84%
Change (1 year)
-42.66%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Orthocell Limited (OCC)
Category
Healthcare
Operating Margin for Orthocell Limited (OCC)
Operating Margin as of November 2026 TTM: -161.15%
According to Orthocell Limited's latest financial reports, its current operating margin (TTM) is -161.15%. At the end of 2025 the company had an operating margin of -185.09%.
Operating Margin history for Orthocell Limited from 2013 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -161.15% | -12.93% |
| 2025 | -185.09% | -15.78% |
| 2024 | -219.76% | -9.56% |
| 2023 | -242.98% | -67.71% |
| 2022 | -752.40% | -34.37% |
| 2021 | -1,146.34% | -12.90% |
| 2020 | -1,316.07% | 46.14% |
| 2019 | -900.57% | -30.57% |
| 2018 | -1,297.18% | 11.49% |
| 2017 | -1,163.51% | 44.83% |
| 2016 | -803.37% | 26.40% |
| 2015 | -635.59% | 61.10% |
| 2014 | -394.52% | 53.46% |
| 2013 | -257.09% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.24% |
US
|
|
| -149.01% | -99.08% |
US
|
|
| 25.57% | -100.16% |
AU
|
|
| 31.23% | -100.19% |
BE
|
|
| 29.35% | -100.18% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Orthocell Limited's operating margin
What is Orthocell Limited's operating margin?
Orthocell Limited's operating margin is -161.15%, as of Nov 2026.
What was Orthocell Limited's operating margin in 2025?
In 2025, Orthocell Limited's operating margin was -185.09%, compared with -219.76% in 2024.
How has Orthocell Limited's operating margin changed since 2020?
From 2020 to 2025, Orthocell Limited's operating margin was highest in 2025 (-185.09%) and lowest in 2020 (-1,316.07%).
How does Orthocell Limited's operating margin compare with similar companies?
Orthocell Limited's operating margin (-161.15%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.